The National Surgical Adjuvant Breast and Bowel Project (NSABP) is leading the STAR clinical trial—one of the largest trials of on breast cancer prevention ever undertaken. STAR, or Study of Tamoxifen and Raloxifene, is investigating whether the drugs tamoxifen (brand name, Nolvadex) and raloxifene (Evista), help prevent breast cancer in women at high risk for disease. In 2007, initial results of STAR and other clinical trials led to the FDA's approval of raloxifene to help prevent invasive breast cancer in post-menopausal women at high risk of the disease. High risk women include those with a strong family history of the disease, history (and results) of breast biopsies, age when a women began menstruating, and other factors. The final results of the STAR trial will help provide more insight on breast cancer prevention.
Recruitment for the STAR trial is now closed and researchers are evaluating data. The STAR trial recruited volunteers from more than 400 centers across the United States, Puerto Rico, and Canada. In all, researchers enrolled more than 19,000 post-menopausal women of all races at increased risk of breast cancer. In addition to determining if tamoxifen and raloxifene can prevent breast cancer, the study is also investigating whether there are additional benefits of raloxifene versus tamoxifen.
According to the NSABP, STAR is the first trial to compare a drug proven to reduce the chance of developing breast cancer with another drug that has the potential to reduce breast cancer risk. All participants received either tamoxifen or raloxifene and took the drug for five years. No patients received a placebo, or inactive pill.
Significant efforts were made to select qualified centers in as many geographical areas as possible so that STAR was accessible to a large number of women seeking a possible breast cancer prevention option. The STAR centers are located at major medical centers and university hospitals, at community hospitals, health maintenance organizations, Community Clinical Oncology Programs (CCOPs), and in physician practice groups. Click here to go to the NSABP website to see a list of centers participating in the trial.
The STAR study is supported by the National Cancer Institute (NCI), Eli Lilly and Company (who markets Evista/raloxifene for the treatment of osteoporosis), and Zeneca Pharmaceuticals.
Prior Research on Breast Cancer Prevention
The May 1999 opening of the Study of Tamoxifen and Raloxifene (STAR) trial followed closely on the heels of the NSABP's first breast cancer prevention trial, in which researchers found that women at high risk of breast cancer who took tamoxifen experienced a 49% decrease in the incidence of invasive breast cancer compared to those who did not receive the drug and received a placebo (inactive pill) instead. The study showed that women taking tamoxifen also had fewer diagnoses of non-invasive breast cancer, such as ductal carcinoma in situ (DCIS).
The original breast cancer prevention clinical trial ran from April 1992 to1998 (women had been participating in the trial for approximately four years). The 13,388 women who participated in the breast cancer prevention trial were selected by chance to receive either tamoxifen or a placebo. The study was double-blinded in that neither the participant nor her physician knew which pill she was receiving. Double-blind studies allow researchers to clearly see what the true benefits and side effects of a drug or treatment may be without the influence of other factors. The breast cancer prevention trial also aimed to determine whether tamoxifen decreased the number of heart attacks and reduced the number of bone fractures in these women. The results of the first breast cancer prevention trial revealed that women in the tamoxifen group had fewer hip, wrist, and spine fractures than women in the placebo group. There was no difference in the number of heart attacks between the two groups.
Return to Breast Cancer Treatment Main Menu
Copyright 1997-2024 Imaginis® Corporation. All rights reserved. Imaginis® is a registered service mark of Imaginis® Corporation, a health services company. All other trademarks and copyrights are property of their respective owners. Note: Use of this online service is subject to the disclaimer and the terms and conditions contained herein. Information found within the Imaginis.com website or in other sites linked to from Imaginis.com is provided for educational purposes only and is not intended to be used as a substitute for diagnosis and treatment by a medical doctor. Imaginis® does not endorse and has no responsibility for the content of any other sites listed on Imaginis.com, and provides links and references merely as a convenience to its users. Seek immediate medical attention if your condition is urgent. Imaginis® - The Breast Cancer Resource